Adia Nutrition Inc. Announces Landmark Autism Spectrum Disorder Clinical Study Now Live on ClinicalTrials.gov
MWN-AI** Summary
Adia Nutrition Inc. (OTCQB: ADIA), based in Winter Park, Florida, has announced a significant milestone in advancing healthcare focused on Autism Spectrum Disorder (ASD). Their patent-pending clinical study, which evaluates the effects of intravenous glutathione combined with umbilical cord blood-derived stem cells and exosomes (AdiaVita) versus glutathione alone, is now live on ClinicalTrials.gov (study NCT07304440). This randomized interventional trial aims to recruit around 100 children aged 3-12 diagnosed with ASD, assessing primary outcomes based on changes in Autism Treatment Evaluation Checklist (ATEC) scores over a two-year follow-up period.
The study received independent Institutional Review Board (IRB) approval in December 2025 and is indicative of Adia Nutrition’s commitment to transparency and rigorous research in regenerative therapies for neurodevelopmental conditions. Larry Powalisz, the CEO of Adia Nutrition, expressed excitement about this advancement, emphasizing the potential new treatment options for families affected by autism. Recruitment for the trial is expected to start shortly, enhancing prospects for generating valuable clinical data in the field.
Beyond the ASD study, Adia Nutrition Inc. continues to expand its operations through the offering of various regenerative and stem cell therapies via its Adia Med clinics. The company also generates revenue from service fees, product sales, and partnerships with health practitioners, with a focus on holistic wellness and innovation.
As a company positioned to lead in regenerative medicine and innovative healthcare solutions, Adia Nutrition is on a growth trajectory that embraces partnerships and further clinical investigations in the coming years. For further details about the clinical study and company offerings, interested parties can visit their official websites.
MWN-AI** Analysis
Adia Nutrition Inc. (OTCQB: ADIA) has made a significant leap in positioning itself as a key player in the burgeoning field of regenerative medicine, particularly in addressing Autism Spectrum Disorder (ASD). The initiation of their clinical trial NCT07304440, which focuses on the effects of intravenous glutathione and umbilical cord blood-derived stem cells, marks an important milestone for the company. As they begin enrollment for key demographic segments — children aged 3-12 with confirmed ASD — this development could potentially enhance their product offerings and market reach.
Investors should consider the implications of this trial. If results show statistically significant improvements in ATEC scores — particularly in critical areas such as speech and sociability — it may not only validate the efficacy of Adia's therapeutic approach but could also position the company favorably in the treatment landscape for ASD. Given the increasing prevalence and societal impact of autism, a successful outcome could drive demand for Adia's services and products, translating to higher revenues and potential stock appreciation.
Moreover, the strategic partnerships that Adia seeks to cultivate with healthcare practitioners and clinic owners for the integration of their therapies presents an avenue for robust revenue growth. The company’s diversified revenue streams, including service fees and product sales, coupled with their expansion plans, indicate a strong business model poised for scalability.
However, no investment is without risk. Investors should remain cognizant of the uncertainties associated with clinical trials and the regulatory landscape surrounding regenerative therapies. Moreover, Adia's performance will hinge on the outcomes of ongoing research endeavors and market acceptance of their innovative treatment solutions.
In summary, ADIA represents a compelling opportunity in the healthcare sector, particularly for those willing to navigate the associated risks. With careful monitoring of trial outcomes and market developments, Adia Nutrition could emerge as a formidable competitor in regenerative medicine.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Winter Park, Florida--(Newsfile Corp. - January 5, 2026) - Adia Nutrition Inc. (OTCQB: ADIA), an emerging leader in regenerative medicine through its subsidiary Adia Med, today announced that its patent-pending clinical study targeting Autism Spectrum Disorder (ASD) has gone live on ClinicalTrials.gov, marking a significant advancement in the company's research pipeline.
To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/10520/279460_adia.jpg
The randomized interventional study, titled "Adia Med of Winter Park LLC Autism Spectrum Disorder Research Study," aims to enroll approximately 100 children aged 3-12 with confirmed ASD. It evaluates the potential benefits of intravenous glutathione combined with umbilical cord blood-derived stem cells and exosomes (AdiaVita) compared to glutathione alone. Primary outcomes focus on changes in Autism Treatment Evaluation Checklist (ATEC) scores, assessing improvements in speech, sociability, sensory awareness, and behavior. The trial includes a 24-month follow-up period, with patient recruitment beginning in January 2026.
Following independent IRB approval from BeyondBound in December 2025, the study completed the ClinicalTrials.gov review process and is now publicly accessible. This development positions Adia Nutrition to generate valuable clinical data in the growing field of regenerative therapies for neurodevelopmental conditions.
"This milestone of going live on ClinicalTrials.gov marks a significant step forward in our commitment to rigorous, transparent research," said Larry Powalisz, CEO of Adia Nutrition Inc. "We are excited to advance potential new options for children and families impacted by autism, building on our expertise in regenerative therapies. We look forward to starting recruitment soon-likely within the next week or two-and will provide an update as soon as it officially begins. This study will serve as a foundational model for additional clinical investigations planned for 2026."
The full details of the study, including eligibility criteria and enrollment information, can be found on ClinicalTrials.gov here: https://clinicaltrials.gov/study/NCT07304440
For questions, inquiries, or additional information, please contact Larry Powalisz at ceo@adiamed.com or by phone at 321-788-0850.
Clinic owners and healthcare practitioners interested in licensing the Adia Med name or integrating Adia's regenerative therapies into their practice are encouraged to reach out directly. Strategic partnerships are welcomed as part of Adia's continued mission to expand access to advanced stem cell solutions.
About ADIA Nutrition Inc.:
Adia Nutrition Inc. (OTCQB: ADIA), based in Winter Park, Florida, is a publicly traded company advancing healthcare through innovation. The company specializes in sales of stem cell and regenerative products, such as AdiaVita and AdiaLink, through its lab division, Adia Labs LLC, which is expanding to include insurance-billable wound care products. Adia is also growing nationwide with Adia Med clinics, specializing in orthopedic, pain management, and wound repair. Adia Med clinics also offer specialized regenerative treatments like stem cell therapies and platelet-rich plasma (PRP), advanced treatments including therapeutic plasma exchange (TPE) and autologous hematopoietic stem cell transplantation (aHSCT), and wound repair services.
Revenue is generated through service fees, product sales, equity stakes, and billing insurance for healthcare treatments. Additionally, Adia Nutrition Inc. invests in aligned businesses such as Cement Factory LLC, a nutrition and supplement company with shared values and a focus on health and wellness. Through bold partnerships with top-tier medical entities and unwavering dedication to standardized, FDA-approved lab protocols, Adia Nutrition Inc. is revolutionizing healthcare, igniting a nationwide movement to empower communities with groundbreaking regenerative solutions and vibrant, holistic wellness.
Website: www.adianutrition.com
Website: www.adiamed.com
Website: www.adialabs.com
Website: www.cementfactory.co
Twitter (X): @ADIA_Nutrition
Safe Harbor: This Press Release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on the current plans and expectations of management and are subject to a few uncertainties and risks that could significantly affect the company's current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company's business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission and OTC Markets, Inc. OTC Disclosure and News Service. The company undertakes no obligation to publicly update or revise any forward-looking statements, because of new information, future events or otherwise.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/279460
FAQ**
How is Adia Nutrition Inc (ADIA) leveraging the growing trend of regenerative medicine in Winter Park, Florida, particularly regarding its recent clinical trial for Autism Spectrum Disorder (ASD)?
What specific partnerships or collaborations is Adia Nutrition Inc (ADIA) pursuing in Winter Park to enhance its research and clinical offerings in regenerative therapies for neurodevelopmental conditions?
In what ways might the outcomes of the clinical trial initiated by Adia Nutrition Inc (ADIA) influence opportunities for other healthcare practices in Winter Park?
How does the business model of Adia Nutrition Inc (ADIA), which includes both product sales and service fees, reflect the healthcare landscape in Winter Park, Florida, especially in relation to regenerative therapies?
**MWN-AI FAQ is based on asking OpenAI questions about Adia Nutrition Inc (OTC: ADIA).
NASDAQ: ADIA
ADIA Trading
-4.31% G/L:
$0.1746 Last:
214,315 Volume:
$0.182458 Open:
